Alembic Pharmaceuticals Cash Flow
₹833.90-0.04%
- Market cap
- ₹16,391 crore
- P/E
- 23.6
- P/B
- 2.89
- ROE
- 12.4%
- Dividend yield
- 1.44%
Alembic Pharmaceuticals cash flow statement as of 7 October 2026.
Alembic Pharmaceuticals cash flow statement
Financial years, newest first. Negative figures are cash outflows.
| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operating activities | — | 724 | 803 | 88 | 783 |
| Cash from investing activities | — | -448 | -321 | -568 | -506 |
| Cash from financing activities | — | -262 | -438 | 444 | -164 |
| Net cash flow | — | 14 | 45 | -37 | 113 |
| Capital expenditure | — | — | — | — | — |
| Free cash flow | — | 281 | 476 | -476 | 288 |
Source: Company filings, in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Same Data For Peers
Trade Alembic Pharmaceuticals With ATS
Track APLLTD live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.